Anaesthesia in patients with drug-eluting stents

Current Opinion in Anaesthesiology

Volumn 21, Issue 1, 2008, Pages 55-59

  Metzler, Helfried ^a   Huber, Kurt ^b   Kozek Langenecker, Sibylle ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Aspirin; Clopidogrel; Drug eluting stents; Dual antiplatelet drug therapy; Percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANESTHESIA; ANESTHESIST; BLEEDING; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ANESTHESIA; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC;

EID: 38149064418     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282f357b6     Document Type: Review

References (42)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:e85-e151.
2. Serruys PW, Kutryk MJB, Ong ATL. Coronary-artery stents. N Engl J Med 2006; 354:483-495.
3. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical treatment with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516.
4. Farb A, Boam AB. Stent thrombosis redux: the FDA perspective. N Engl J Med 2007; 356:984-987. This is an interesting brief comment on the background of the worldwide actual cardiological concern and debate.
5. Slottow TLP, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis. Cathet Cardiovasc Interv 2007; 69:1064-1074.
6. Beohar N, Davidson CJ, Kip KE. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992-2000.
7. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label of drug-eluting stents. JAMA 2007; 297:2001-2009.
8. Kastrati A, Schömig A. Drug-eluting stents. J Am Coll Cardiol 2007; 50:146-148.
9. Kaul S, Shah PK, Diamond GA. As time goes by. Current status and future directions in the controversy over stenting. J Am Coll Cardiol 2007; 50:128-137. This is a brief cardiological review on the current debate of the problems of DES.
10. Holmes DR, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents. J Am Coll Cardiol 2007; 50:109-118.
11. Cook S, Wenaweser P, Togni M, et al. Incomplete stent appostion and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007; 115:2426-2434.
12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment in elevation. N Engl J Med 2001; 345:494-502.
13. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
14. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal. A special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456-459.
15. Pfisterer M, Brunner La-Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 2006; 48:2584-2591.
16. Spertus JA, Kettelkampf R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement (Results form the PREMIER Registry). Circulation 2006; 113:2803-2809.
17. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and noncardiac surgery: a prospective outcome study. Br J Anaesth 2006; 96:686-693.
18. Schouten O, Van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49:122-124.
19. De Souza DG, Baum VC, Ballert NM. Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology 2007; 106:1057-1059.
20. Charbucinska KN, Godet G, Itani O, et al. Anitcoagulation management for patients with drug-eluting stents undergoing vascular surgery. Anesth Analg 2006; 103:261-263.
21. Broad L, Lee T, Conroy M, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, noncardiac surgery. Br J Anaesth 2007; 98:19-22.
22. Burger W, Chemnitus JM, Kneissl GD. Low-dose aspirin for secondary cardiovascular prevention. Cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med 2005; 257:399-414.
23. Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur Heart J 2006; 8:G38-G45.
24. Michelson AD, Frelinger AL, Furman MI. Current opinions in platelet function testing. Am J Cardiol 2006; 98:4N-10N. This is a brief overview by an outstanding expert in this field on current assays of platelet function monitoring.
25. Agarwal S, Coakely M, Reddy K. Quantifying the effect of antiplatelet therapy. Anesthesiology 2006; 105:676-683.
26. Schäfer A, Bonz AW, Eigenthaler M, et al. Late thrombosis of a drug-eluting stent during combined antiplatelet therapy in a clopdigrel nonresponsive diabetic patient: Shall we routinely test platelet function? Thromb Haemost 2007; 97:862-885.
27. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function. Circulation 2007; 115:3156-3164.
28. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection on clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3:85-92.
29. Bracey AW, Grigore AM, Nussmeier NA. Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures. Am J Cardiol 2006; 98:25N-32N.
30. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26:804-847.
31. ACC/AHA/SCAI 2005. Guideline update for percutaneous coronary intervention: summary article. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2006; 47:216-235.
32. US Food and Drug Administration. Update to FCA statement on coronary drug-eluting stents. http://www.fda.gov/cdrh/news/010407.html. [Accessed 11 April 2007]
33. Grines CL, Bonow RO, Gasey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813-818. This is an excellent actual recommendation of involved American societies about the risk of premature discontinuation of antiplatelet drugs.
34. Albaladejo P, Marret E, Piriou V, et al. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. Br J Anaesth 2006; 97:580-585. This provides excellent recommendations of an interdisciplinary French Task Force.
35. Howard-Alpe GM, De Bono J, Hudsmith L, et al. Coronary artery stents and noncardiac surgery. Br J Anaesth 2007; 98:560-574.
36. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49:2145-2150. This is one of the recent reviews by a cardiologist on the perioperative management of patients with coronary stents presenting for surgery.
37. Collet JP, Montalescot G. Premature withdrawal and alternative therapies to dual oral antiplatelet therapy. Eur Heart J 2006; 8:G46-G52.
38. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99:316-328.
39. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis. Biological mechanisms and clinical implications. Circulation 2007; 115:1051-1058.
40. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126-2130.
41. Rabbat MG, Bavry AA, Bhatt DL, Ellis SG. Understanding and minimizing late thrombosis of drug-eluting stents. Cleveland Clinic J Med 2007; 74:129-136.
42. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:1971-1996.